Glial fibrillary acidic protein mRNA (GFAP mRNA)

GFAP mRNA refers to the messenger RNA transcript produced from the glial fibrillary acidic protein (GFAP) gene. GFAP mRNA is not itself a protein, receptor, enzyme, or classic "drug target"—rather, it is the intermediary molecule that encodes GFAP protein, a type III intermediate filament important for astrocyte structure and function. GFAP mRNA is widely studied as a measure of astrocyte activity, differentiation, and pathology in neurodevelopment and disease. Its levels are regulated by various growth factors, cytokines, and nuclear receptor hormones[2][6]. Notably, alternative splicing of GFAP mRNA produces different isoforms, such as GFAPα and GFAPδ, which play roles in brain development and glioma biology[3][5]. Changes in GFAP mRNA expression are associated with central nervous system pathology, making it useful as a biomarker in research, but it is not a direct therapeutic target like a receptor or enzyme. The canonical therapeutic target is the GFAP protein, not its mRNA[1][4]. **Note:** - The query is technically incorrect if "therapeutic target" is strictly defined, as GFAP mRNA is not a direct drug target but may be monitored or manipulated in research settings (for example, by antisense oligonucleotides or gene silencing approaches in experimental models)[3]. - Drugs do not directly "target" GFAP mRNA in clinical practice; research approaches sometimes modulate GFAP mRNA, but no approved therapies target it directly.

Other names

GFAP transcriptGFAP gene transcriptGlial fibrillary acidic protein transcript